---
figid: PMC8353874__12935_2021_2107_Fig1_HTML
figtitle: 'Triple-negative breast cancer: understanding Wnt signaling in drug resistance'
organisms:
- Homo sapiens
- Lareunionomyces loeiensis
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8353874
filename: 12935_2021_2107_Fig1_HTML.jpg
figlink: /pmc/articles/PMC8353874/figure/Fig1/
number: F1
caption: An overview of the Wnt signaling pathway. a In the absence of Wnt ligands
  (Wnt-Off state), β-catenin is released from the cytomembrane, sequestered in a destructive
  protein complex, that is composed of adenomatous polyposis coli (APC), the scaffolding
  protein axin, casein kinase 1 (CK1), and glycogen synthase kinase 3β (GSK-3β). The
  Dkks, WIF, and SFRPs act as antagonists. The phosphorylations by CK1 and GSK-3β
  recruit β-propeller domain of the E3 ubiquitin ligase (β TrCP) and subsequently
  cause the β catenin proteasomal degradation and transcriptional repression of Wnt
  target genes. b Canonical Wnt/β-catenin signaling is activated by binding of Wnt
  ligands (Wnt-On state) to a receptor complex composed of FZD and LRP 5/6. The recruitment
  of phosphorylated DVL to FZD inhibits the APC/CK1/GSK-3β destruction complex and
  blockade of β-catenin by GSK-3β. Accumulated β-catenin in the cytoplasm translocate
  into the nucleus, where it regulates target gene expression with the Tcf/Lef family
  of transcription factors. c In Wnt planar cell polarity (Wnt-PCP) signaling, Wnt
  binds multiple receptors including FZD and co-receptors ROR and Ryk. This activates
  Rho-A and RAK1/Cdc42, which activate ROCK and JNK (c-Jun N-terminal kinase), respectively,
  leading to actin cytoskeleton rearrangement and cell polarity through AP-1. d In
  ON-state non-canonical Wnt/Ca2+ signaling pathway, the binding of Wnt promotes FZD-mediated
  activation of G proteins and Ryk and initiates the release of Ca2+ from intracellular
  stores and activation of Ca2+-dependent effector molecules. Several Ca2+-sensitive
  targets, i.e., PKC, CamKII, and calcineurin, have been identified as downstream
  of the Wnt/Ca2+ pathway
papertitle: 'Triple-negative breast cancer: understanding Wnt signaling in drug resistance.'
reftext: Parnaz Merikhian, et al. Cancer Cell Int. 2021;21:419.
year: '2021'
doi: 10.1186/s12935-021-02107-3
journal_title: Cancer Cell International
journal_nlm_ta: Cancer Cell Int
publisher_name: BioMed Central
keywords: Triple negative breast cancers (TNBCs) | Wnt/β-catenin | Drug resistance
  | Tumorigenesis | Combination therapy
automl_pathway: 0.8293621
figid_alias: PMC8353874__F1
figtype: Figure
redirect_from: /figures/PMC8353874__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8353874__12935_2021_2107_Fig1_HTML.html
  '@type': Dataset
  description: An overview of the Wnt signaling pathway. a In the absence of Wnt ligands
    (Wnt-Off state), β-catenin is released from the cytomembrane, sequestered in a
    destructive protein complex, that is composed of adenomatous polyposis coli (APC),
    the scaffolding protein axin, casein kinase 1 (CK1), and glycogen synthase kinase
    3β (GSK-3β). The Dkks, WIF, and SFRPs act as antagonists. The phosphorylations
    by CK1 and GSK-3β recruit β-propeller domain of the E3 ubiquitin ligase (β TrCP)
    and subsequently cause the β catenin proteasomal degradation and transcriptional
    repression of Wnt target genes. b Canonical Wnt/β-catenin signaling is activated
    by binding of Wnt ligands (Wnt-On state) to a receptor complex composed of FZD
    and LRP 5/6. The recruitment of phosphorylated DVL to FZD inhibits the APC/CK1/GSK-3β
    destruction complex and blockade of β-catenin by GSK-3β. Accumulated β-catenin
    in the cytoplasm translocate into the nucleus, where it regulates target gene
    expression with the Tcf/Lef family of transcription factors. c In Wnt planar cell
    polarity (Wnt-PCP) signaling, Wnt binds multiple receptors including FZD and co-receptors
    ROR and Ryk. This activates Rho-A and RAK1/Cdc42, which activate ROCK and JNK
    (c-Jun N-terminal kinase), respectively, leading to actin cytoskeleton rearrangement
    and cell polarity through AP-1. d In ON-state non-canonical Wnt/Ca2+ signaling
    pathway, the binding of Wnt promotes FZD-mediated activation of G proteins and
    Ryk and initiates the release of Ca2+ from intracellular stores and activation
    of Ca2+-dependent effector molecules. Several Ca2+-sensitive targets, i.e., PKC,
    CamKII, and calcineurin, have been identified as downstream of the Wnt/Ca2+ pathway
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CDH1
  - CDH10
  - CDH11
  - CDH12
  - CDH13
  - CDH15
  - CDH16
  - CDH17
  - CDH18
  - CDH19
  - CDH2
  - CDH20
  - CDH22
  - CDH24
  - CDH3
  - CDH4
  - CDH5
  - CDH6
  - CDH7
  - CDH8
  - CDH9
  - CTNND1
  - IGSF1
  - NOP2
  - RASA1
  - TRPA1
  - BRD8
  - NSUN5
  - CTNNB1
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - LRP6
  - LRP5
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - HNF4A
  - RNASE9
  - CDC42
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - GSK3B
  - APC
  - PROC
  - AXIN1
  - AXIN2
  - DVL1
  - DVL1P1
  - DVL2
  - DVL3
  - MAPK8
  - MAPK9
  - MAPK10
  - JUN
  - FOS
  - FOSB
  - JUNB
  - JUND
  - FOSL1
  - FOSL2
  - CSNK1A1
  - KRT1
  - CSNK1A1L
  - LINC-ROR
  - ROR1
  - ROR2
  - BTRC
  - AN
  - DAAM1
  - RHOA
  - ROCK1
  - ROCK2
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - RSPO1
  - MUC5AC
  - GNAO1
  - GNAI1
  - GNAI2
  - GNAI3
  - GNAT1
  - GNAT2
  - GNAT3
  - GNAZ
  - GNAS
  - GNAL
  - GNAQ
  - GNA11
  - GNA14
  - GNA15
  - GNA12
  - GNA13
  - CAMK2G
  - NFATC1
  - NFATC2
  - NFATC3
  - NFATC4
  - NFAT5
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - NFKB1
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - PROM1
  - CD44
  - EGFR
  - CCND1
  - HNF1A
  - TCF7
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - mip120
  - MetRS
  - Glg1
  - MTA1-like
  - Pi3K92E
  - p120ctn
  - alpha-Cat
  - arm
  - Tnks
  - fz
  - arr
  - Wnt5
  - Wnt4
  - wg
  - Wnt2
  - pan
  - Cdc42
  - sgg
  - gskt
  - Apc
  - Apc2
  - Axn
  - Fs(3)Apc
  - dsh
  - bsk
  - Jra
  - AP-1gamma
  - kay
  - CkIalpha
  - gish
  - Ror
  - slmb
  - svp
  - man
  - alpha-Man-IIa
  - an
  - DAAM
  - Rho1
  - Rok
  - Act5C
  - Act42A
  - Act57B
  - Act79B
  - Act88F
  - Act87E
  - CaMKII
  - NFAT
  - norpA
  - sl
  - Plc21C
  - Dif
  - dl
  - Rel
  - CrebB
  - CrebA
  - Egfr
  - mid
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
---
